The Zhitong Finance App learned that according to news from the Hong Kong Stock Exchange on May 26, QuantumPharm Inc. (Jingtai Technology) passed the Hong Kong Stock Exchange main board listing hearing, and CITIC Securities was the sole sponsor.

According to the prospectus, Jingtai Technology is an innovative R&D platform based on quantum physics, empowered by artificial intelligence, and driven by robots. The company uses a combination of first-principles computation based on quantum physics, artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation to provide pharmaceutical and material science R&D solutions and services to global and domestic companies in the pharmaceutical and materials science industries (including agricultural technology, energy and novel chemicals, and cosmetics).

According to Frost & Sullivan, Jingtai Technology is one of the few pharmaceutical and material science research and development companies in the world that also has first-principles calculations based on quantum physics, artificial intelligence technology, and automated wet laboratory capabilities.

Since 2018, Jingtai Technology has made significant contributions in the field of drug design and discovery, improving speed, scale, novelty and success rate. The company recently expanded its business into the fields of materials science (such as the design and discovery of bio-based materials, application of novel compounds, novel chemical surfactants and catalysts, and cosmetics in agricultural technology) and automation (such as automated chemical synthesis), and is committed to continuing to expand this business in the future.

Additionally, Jingtai Technology has a diverse customer base, ranging from startups to global biotech and pharmaceutical companies. According to Frost & Sullivan, the company's customer base includes 16 of the top 20 global biotechnology and pharmaceutical companies (based on 2022 revenue). The company has established long-term and stable partnerships with many world-leading biotechnology and pharmaceutical enterprise groups such as Pfizer, Johnson & Johnson, and Merck Group of Germany, most of which are repeat customers.

Among them, Jingtai Technology's crystal structure prediction capabilities and long-term cooperation with Pfizer ultimately enabled the company to help shorten the time required to confirm the best crystalline drug form for Paxlovid development and production, making it the world's first FDA-approved COVID-19 oral therapy at a critical moment in the global fight against SARS-CoV-2.

Since its establishment, Jingtai Technology has received strong investment and support from world-renowned private equity investors and strategic investors, including Sequoia, Mirae Asset, Google, Tencent, China Life Insurance Chengda and Wuyuan Capital.

On the financial side, in 2021, 2022, and 2023, Jingtai Technology achieved revenue of about 62.799 million yuan, 133 million yuan, and 174 million yuan respectively; during the same period, losses during the year were about 2,137 billion yuan, 1,438 billion yuan, and 1,906 billion yuan, respectively.